Locations:
Search IconSearch

Blood Cancers

cells with idiopathic multicentric Castleman Disease
February 20, 2025/Cancer/Blood Cancers

Study Offers New Insights into Idiopathic Multicentric Castleman Disease

Highlighting treatment gaps and challenges in the management of rare condition

CAR T-cell therapy
February 18, 2025/Cancer/Blood Cancers

Top Myths About CAR T-Cell Therapy for Multiple Myeloma

Explaining common misconceptions about chimeric antigen receptor therapy

3D rendering of bispecific antibodies
December 17, 2024/Cancer/Blood Cancers

Efficacy and Safety Outcomes of Bispecific Antibodies

Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

CAR T-cell therapy
December 9, 2024/Cancer/Blood Cancers

Major Study Finds CAR T-Cell Therapy Safe and Effective for Older Patients With B-Cell Acute Lymphoblastic Leukemia

Offers a new option for patients 60 and older with relapsed/refractory disease

Cancer patient being hugged by a loved one
September 4, 2024/Cancer/Blood Cancers

Study Finds Immunotherapy Increases Three-Year Survival in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone

car T-cells
June 3, 2024/Cancer/Blood Cancers

CAR T-Cell Treatment Offers Hope for Richter Transformation

Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel

Dr. Mukherjee at Cleveland Clinic
April 1, 2024/Cancer/Blood Cancers

Many Patients with “Indolent” Systemic Mastocytosis Experience Rapid Decline and Lower Survival

First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention

BackPage 3 of 6Next

Advertisement

Ad